Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) Non Operating Income: 2023-2025

Historic Non Operating Income for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to -$1.4 million.

  • Inhibrx Biosciences' Non Operating Income fell 149.23% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 100.05%. This contributed to the annual value of $2.0 billion for FY2024, which is 9947.45% up from last year.
  • Latest data reveals that Inhibrx Biosciences reported Non Operating Income of -$1.4 million as of Q3 2025, which was down 14.33% from -$1.3 million recorded in Q2 2025.
  • Inhibrx Biosciences' Non Operating Income's 5-year high stood at $2.0 billion during Q2 2024, with a 5-year trough of -$6.0 million in Q3 2023.
  • In the last 3 years, Inhibrx Biosciences' Non Operating Income had a median value of -$1.4 million in 2025 and averaged $200.1 million.
  • In the last 5 years, Inhibrx Biosciences' Non Operating Income soared by 39,302.16% in 2024 and then slumped by 149.23% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Non Operating Income (Quarterly) stood at -$3.7 million in 2023, then surged by 155.98% to $2.1 million in 2024, then slumped by 149.23% to -$1.4 million in 2025.
  • Its Non Operating Income stands at -$1.4 million for Q3 2025, versus -$1.3 million for Q2 2025 and -$410,000 for Q1 2025.